Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy

Cited by (999)

Items 201–300 of 999

1. Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer
   Eric E. Fox, Thomas Oliver, Melissa M. Rowe, Sunil Thomas, Yousef Zakharia, Paul B. Gilman, Alexander J. Muller, George C. Prendergast · 2018 · Frontiers in Oncology
2. Genotyping and Expression Analysis of IDO2 in Human Pancreatic Cancer: A Novel, Active Target
   Agnieszka Katarzyna Witkiewicz, Christina L. Costantino, Richard A. Metz, Alexander J. Muller, George C. Prendergast, Charles J. Yeo, Jonathan Robert Brody · 2009 · Journal of the American College of Surgeons
3. Exiguamine A, an Indoleamine-2,3-dioxygenase (IDO) Inhibitor Isolated from the Marine Sponge Neopetrosia exigua
   Harry C. Brastianos, Eduardo Vottero, Brian O. Patrick, Rob W. M. van Soest, Teatulohi K. Matainaho, A. Grant Mauk, Raymond J. Andersen · 2006 · Journal of the American Chemical Society
4. Revisiting caspases in sepsis
   Aziz, M, Jacob, A, Wang, P · 2014 · Cell Death & Disease
5. The metabolic advantage of tumor cells
   Maurice Israël, Laurent H. Schwartz · 2011 · Molecular Cancer
6. Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors
   Amr K. A. Bass, Mona S. El‐Zoghbi, El-Shimaa M. Nageeb, Mamdouh F. A. Mohamed, Mohamed Badr, Gamal El‐Din A. Abuo‐Rahma · 2020 · European Journal of Medicinal Chemistry
7. Epigenetic polypharmacology: A new frontier for epi‐drug discovery
   Daniela Tomaselli, Alessia Lucidi, Dante Rotili, Antonello Mai · 2019 · Medicinal Research Reviews
8. Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality
   Lisa K. Jasperson, Christoph Marcus Bucher, Angela Panoskaltsis‐Mortari, Andrew L. Mellor, David H. Munn, Bruce R. Blazar · 2009 · Blood
9. Interaction of tryptophan derivatives with SLC6A14 (ATB0,+) reveals the potential of the transporter as a drug target for cancer chemotherapy
   Senthil K. Karunakaran, Nagavedi Siddaramappa Umapathy, Muthusamy Thangaraju, Takahiro Hatanaka, Shiro Itagaki, David H. Munn, Puttur Devi Prasad, Vadivel Ganapathy · 2008 · Biochemical Journal
10. A Cisplatin‐Loaded Immunochemotherapeutic Nanohybrid Bearing Immune Checkpoint Inhibitors for Enhanced Cervical Cancer Therapy
    Na Wang, Zhigang Wang, Zoufeng Xu, Xianfeng Chen, Guangyu Zhu · 2018 · Angewandte Chemie International Edition
11. Nanosensor Detection of an Immunoregulatory Tryptophan Influx/Kynurenine Efflux Cycle
    Thijs Kaper, Loren L. Looger, Hitomi Takanaga, Michael Platten, Lawrence Steinman, Wolf Bernd Frommer · 2007 · PLoS Biology
12. Curcumin Suppresses the Induction of Indoleamine 2,3-Dioxygenase by Blocking the Janus-activated Kinase-Protein Kinase Cδ-STAT1 Signaling Pathway in Interferon-γ-stimulated Murine Dendritic Cells
    Young-Il Jeong, Sang Woo Kim, In Duk Jung, Jun Sik Lee, Jeong Hyun Chang, Chang-Min Lee, Sung Hak Chun, Man‐Soo Yoon, Geun Tae Kim, Seok Woo Ryu et al. · 2008 · Journal of Biological Chemistry
13. Mechanism and Localization of CD8 Regulatory T Cells in a Heart Transplant Model of Tolerance
    Xian Liang Li, Séverine Ménoret, Séverine Bézie, Lise Caron, Dominique Chabannes, Marcelo Hill, Franck Albert Halary, Mathieu Angin, Michèle Heslan, Claire Usal et al. · 2010 · The Journal of Immunology
14. Cancer Immunotherapy: Selected Targets and Small‐Molecule Modulators
    Hilmar Weinmann · 2016 · ChemMedChem
15. Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses
    Lauren M.F. Merlo, James B. DuHadaway, James D. Montgomery, Weidan Peng, Peter J. Murray, George C. Prendergast, Andrew J. Caton, Alexander J. Muller, Laura Mandik‐Nayak · 2020 · Frontiers in Immunology
16. Hepatic Tumor Microenvironments and Effects on NK Cell Phenotype and Function
    Julián Piñeiro Fernández, Kimberly A. Luddy, Cathal Harmon, Cliona O’Farrelly · 2019 · International Journal of Molecular Sciences
17. Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer
    Baosheng Chen, David M. Alvarado, Micah S. Iticovici, Nathan S. Kau, Haeseong Park, Parag Jitendra Parikh, Dinesh Kumar Thotala, Matthew A. Ciorba · 2020 · Cancer Immunology Research
18. Opposing Biological Functions of Tryptophan Catabolizing Enzymes During Intracellular Infection
    Senad Divanovic, Nancy M. Sawtell, Aurélien Trompette, Jamie I. Warning, Alexandra Dias, Andrea May Cooper, George S. Yap, Moshe Arditi, Kenichi Shimada, James B. DuHadaway et al. · 2011 · The Journal of Infectious Diseases
19. The Immunoregulatory Enzyme IDO Paradoxically Drives B Cell-Mediated Autoimmunity
    Grant N. Scott, James B. DuHadaway, Elizabeth Pigott, Natalie A. Ridge, George C. Prendergast, Alexander J. Muller, Laura Mandik‐Nayak · 2009 · The Journal of Immunology
20. Marrying Immunotherapy with Chemotherapy: Why Say IDO?
    Alexander J. Muller, George C. Prendergast · 2005 · Cancer Research
21. BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer
    J. Wang, Yunlong Jia, S Zhao, Xiaoling Zhang, Xuhan Wang, Xiaonan Han, Yuqing Wang, Mian Ma, Jiaqi Shi, Longtao Liu · 2017 · Oncogene
22. Engineering Prodrug Nanomedicine for Cancer Immunotherapy
    Bin Yang, Jing Gao, Qing Pei, Hui‐Xiong Xu, Haijun Yu · 2020 · Advanced Science
23. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors
    Alexander J. Muller, William P. Malachowski, George C. Prendergast · 2005 · Expert Opinion on Therapeutic Targets
24. Blocking IDO activity to enhance anti-tumor immunity
    David, H. Munn · 2011 · Frontiers in Bioscience-Elite
25. Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis
    Tsuyoshi Hamada, NaNa Keum, Reiko Nishihara, Shuji Ogino · 2016 · Journal of Gastroenterology
26. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
    Isabelle Opitz, Arnaud Scherpereel, Thierry Berghmans, Ioannis Psallidas, Markus Glatzer, David Rigau Comas, Philippe J. Astoul, Servet Bölükbas, Jeanette Boyd, Johan Coolen et al. · 2020 · European Journal of Cardio-Thoracic Surgery
27. Microbiota and cancer: host cellular mechanisms activated by gut microbial metabolites
    Sofia A. Tsvetikova, Elena I. Koshel · 2020 · International Journal of Medical Microbiology
28. Tumor metabolism as modulator of immune response and tumor progression
    Eva Gottfried, Marina P Kreutz, Andréas Mackensen · 2012 · Seminars in Cancer Biology
29. Tumor immune escape mediated by indoleamine 2,3-dioxygenase
    Μαρία Ζαμανάκου, Anastasios E. Germenis, Vaios Karanikas · 2007 · Immunology Letters
30. Nanoenabled Reversal of IDO1-Mediated Immunosuppression Synergizes with Immunogenic Chemotherapy for Improved Cancer Therapy
    Hua Huang, Cheng‐Tao Jiang, Song Shen, An Liu, Yun-Jiu Gan, Qi‐Song Tong, Sen-Biao Chen, Zhuxin Gao, Jin‐Zhi Du, Jie Cao et al. · 2019 · Nano Letters
31. Dendritic Cells, Indoleamine 2,3 Dioxygenase and Acquired Immune Privilege
    Lei Huang, Babak Baban, Burles Avner Johnson, Andrew L. Mellor · 2010 · International Reviews of Immunology
32. Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia
    Valentina Folgiero, Bianca Maria Goffredo, Perla Filippini, Riccardo Masetti, Giuseppina Bonanno, Roberta Caruso, Valentina Bertaina, Angela Mastronuzzi, Stefania Gaspari, Marco Zecca et al. · 2013 · Oncotarget
33. IDO-expressing regulatory dendritic cells in cancer and chronic infection
    Alexey Popov, Joachim Ludwig Schultze · 2007 · Journal of Molecular Medicine
34. CaCO3-Assisted Preparation of pH-Responsive Immune-Modulating Nanoparticles for Augmented Chemo-Immunotherapy
    Yujie Zhu, Zhijuan Yang, Ziliang Dong, Yimou Gong, Yu Hao, Longlong Tian, Xianzhu Yang, Zhuang Liu, Liangzhu Feng · 2020 · Nano-Micro Letters
35. The footprint of kynurenine pathway in every cancer: a new target for chemotherapy
    Moein Ala · 2021 · European Journal of Pharmacology
36. Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry
    Hatem Hussein Soliman, Bhupendra Rawal, Jimmy Fulp, Ji‐Hyun Lee, Alexis S. Lopez, Marylin M. Bui, Farah K Khalil, Scott Joseph Antonia, Harris G. Yfantis, Dong Hoon Lee et al. · 2013 · Cancer Immunology Immunotherapy
37. Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies
    Ignacio Melero, Oihana Murillo, Juan Dubrot, Sandra Hervás‐Stubbs, José Luis Perez‐Gracia · 2008 · Trends in Pharmacological Sciences
38. Biomimetic nanoparticles directly remodel immunosuppressive microenvironment for boosting glioblastoma immunotherapy
    Tingting Wang, Hao Zhang, Weibao Qiu, Yaobao Han, Hanghang Liu, Zhen Li · 2022 · Bioactive Materials
39. Combinatorial approach to cancer immunotherapy: strength in numbers
    Anna E. Vilgelm, Douglas Buckner Johnson, Ann J. Richmond · 2016 · Journal of Leukocyte Biology
40. Targeting Myelomonocytic Cells to Revert Inflammation-Dependent Cancer Promotion
    Mario P. Colombo, Alberto Mantovani · 2005 · Cancer Research
41. Tryptophan degradation in autoimmune diseases
    Christiane A. Opitz, Wolfgang Wick, Lawrence Steinman, Michael Platten · 2007 · Cellular and Molecular Life Sciences
42. Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors
    David P. Meininger, Leeanne P. Zalameda, Yichin Liu, Lara P. Stepan, Luís Borges, John D. McCarter, Claire L. Sutherland · 2011 · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
43. c-MYC Suppresses BIN1 to Release Poly(ADP-Ribose) Polymerase 1: A Mechanism by Which Cancer Cells Acquire Cisplatin Resistance
    Slovénie Pyndiah, Satoshi Tanida, Kazi Mokim Ahmed, Erica K. Cassimere, Chungyoul Choe, Daitoku Sakamuro · 2011 · Science Signaling
44. Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms
    Bani Mukhopadhyay, Kornel E. Schuebel, Partha Mukhopadhyay, Reşat Çınar, Grzegorz Godlewski, Keming Xiong, Ken Mackie, Martin J. Lizak, Qiaoping Yuan, David A Goldman et al. · 2015 · Hepatology
45. Amino-acid sensing and degrading pathways in immune regulation
    Ursula Grohmann, Giada Mondanelli, Maria Laura Belladonna, Ciriana Orabona, Maria Teresa Pallotta, Alberta Iacono, Paolo Puccetti, Claudia Volpi · 2017 · Cytokine & Growth Factor Reviews
46. The aryl hydrocarbon receptor (AhR) mediates resistance to apoptosis induced in breast cancer cells
    Kanae Bekki, Helena Vogel, Wen Li, Tomohiro Ito, Colleen A. Sweeney, Thomas Haarmann‐Stemmann, Fumio Matsumura, Christoph F. A. Vogel · 2014 · Pesticide Biochemistry and Physiology
47. Post-translational Regulation of Human Indoleamine 2,3-Dioxygenase Activity by Nitric Oxide
    Shane Ross Thomas, Andrew C. Terentis, Hong Cai, Osamu Takikawa, Aviva Levina, Peter A. Lay, Mohammed Freewan, Roland Stocker · 2007 · Journal of Biological Chemistry
48. Highlights of 10 years of immunology in Nature Reviews Immunology
    Ruslan M. Medzhitov, Ethan M. Shevach, Giorgio Trinchieri, Andrew L. Mellor, David H. Munn, Siamon Gordon, Peter Libby, Göran K. Hansson, Ken Shortman, Chen Dong et al. · 2011 · Nature reviews. Immunology
49. Modulation of Cancer-Specific Immune Responses by Amino Acid Degrading Enzymes
    Elina Timosenko, Andreas V. Hadjinicolaou, Vincenzo Cerundolo · 2016 · Immunotherapy
50. Regulating the balance between the kynurenine and serotonin pathways of tryptophan metabolism
    Yang Li, Nan Hu, Dan Yang, Gregory F. Oxenkrug, Qing Yang · 2017 · FEBS Journal
51. Chromatographic analysis of tryptophan metabolites
    Ilona Sadok, Andrzej Gamian, Magdalena Maria Staniszewska · 2017 · Journal of Separation Science
52. A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer
    Rebecca Sophie Kristeleit, Ірина Давиденко, Vadim Shirinkin, Fatima El-Khouly, Igor Bondarenko, Michael Joseph Goodheart, В. А. Горбунова, Carol A. Penning, Jack G. Shi, Xiangdong Liu et al. · 2017 · Gynecologic Oncology
53. Expression of Indoleamine 2,3-Dioxygenase and Correlation With Pathological Malignancy in Gliomas
    Kentaro Mitsuka, Tomoyuki Kawataki, Eiji Satoh, Takayuki Asahara, Toru Horikoshi, Hiroyuki Kinouchi · 2013 · Neurosurgery
54. Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence
    Biagio Ricciuti, Giulia Costanza Leonardi, Paolo Puccetti, Francesca Fallarino, Vanessa Bianconi, Amirhossein Sahebkar, Sara Baglivo, Rita Chiari, Matteo Pirro · 2018 · Pharmacology & Therapeutics
55. Sono/Photodynamic Nanomedicine‐Elicited Cancer Immunotherapy
    Yuce Li, Jun Xie, Wooram Um, Dong Gil You, Seunglee Kwon, Lianbin Zhang, Jintao Zhu, Jae Hyung Park · 2020 · Advanced Functional Materials
56. Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer
    Miho Takao, Aikou Okamoto, Takashi Nikaido, Mitsuyoshi Urashima, Satoshi Takakura, Misato Saito, Motoaki Saito, Sanshiro Okamoto, Osamu Takikawa, Hiroshi Sasaki et al. · 2007 · Oncology Reports
57. Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer
    Srikanth Santhanam, David M. Alvarado, Matthew A. Ciorba · 2015 · Translational research
58. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC)
    Sreenivasa Rao Chandana, Hani M. Babiker, Daruka Mahadevan · 2018 · Expert Opinion on Investigational Drugs
59. Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance
    Andreia Valente, Ana Podolski-Renić, Isabella Poetsch, Nenad R. Filipović, Óscar López, Iztok Turel, Petra Heffeter · 2021 · Drug Resistance Updates
60. High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome
    Martine E.D. Chamuleau, Arjan A. van de Loosdrecht, Corine J. Hess, Jeroen J. W. M. Janssen, Adri Zevenbergen, R Delwel, Peter J.M. Valk, Bob Löwenberg, Gert Jan Ossenkoppele · 2008 · Haematologica
61. Reinstalling Antitumor Immunity by Inhibiting Tumor-Derived Immunosuppressive Molecule IDO through RNA Interference
    Xiufen Zheng, James D. Koropatnick, Mu Li, Xusheng Zhang, Fengjun Ling, Xiubao Ren, Xishan Hao, Hongtao Sun, Costin Vladau, Jacob A. Franek et al. · 2006 · The Journal of Immunology
62. Immunosuppressive Mechanisms of Regulatory Dendritic Cells in Cancer
    Galina V. Shurin, Yang Ma, Michael R. Shurin · 2013 · Cancer Microenvironment
63. Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients’ sera by HPLC and is inducible by IFN-γ
    Sélim Corm, Céline Berthon, Michel Imbenotte, Valéria Biggio, Michel Lhermitte, Caroline Dupont, Isabelle Briche, Bruno Quesnel · 2008 · Leukemia Research
64. C-reactive protein predicts fatigue independently of depression in breast cancer patients prior to chemotherapy
    Maria Pertl, David Hevey, Noreen T. Boyle, Martina M. Hughes, Sonya Collier, Anne-Marie O’Dwyer, Andrew Harkin, M. John Kennedy, Thomas J. Connor · 2013 · Brain Behavior and Immunity
65. Indoleamine 2,3-dioxygenase as a Modifier of Pathogenic Inflammation in Cancer and other Inflammation-Associated Diseases
    George C. Prendergast, Mee Young Chang, Laura Mandik‐Nayak, Richard A. Metz, A. J. Muller · 2011 · Current Medicinal Chemistry
66. Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients
    Yunlong Jia, Hongyan Wang, Yu Wang, Tingting Wang, Miao Wang, Ming Ma, Yuqing Duan, Xianli Meng, Lihua Liu · 2015 · International Journal of Cancer
67. ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer
    Guru Sonpavde, Andrea Necchi, Shilpa Gupta, Gary D. Steinberg, Juergen E. Gschwend, Michiel Simon Van Der Heijden, Nathalie Garzon, Mohammed F. K. Ibrahim, Bradley Raybold, Danny Liaw et al. · 2019 · Future Oncology
68. Tumor Promotion by Tumor-Associated Macrophages
    Porta, Chiara, Kumar, Biswas Subhra, Larghi, Paola, Rubino, Luca, Mancino, Alessandra, Sica, Antonio · 2007 · Advances In Experimental Medicine And Biology
69. The Dendritic Cell-Regulatory T Lymphocyte Crosstalk Contributes to Tumor-Induced Tolerance
    Nona Janikashvili, Bernard Bonnotte, Emmanuel Katsanis, Nicolas Larmonier · 2011 · Clinical and Developmental Immunology
70. Kynurenine-3-monooxygenase: a review of structure, mechanism, and inhibitors
    Jason R. Smith, Joanne F. Jamie, Gilles J. Guillemin · 2015 · Drug Discovery Today
71. Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival
    Debbie M. Ferns, Ido P. Kema, Marrije R. Buist, Hans W. Nijman, Gemma G. Kenter, Ekaterina S. Jordanova · 2015 · OncoImmunology
72. The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy
    Andrew M. K. Law, Elgene Lim, Christopher John Ormandy, David Gallego‐Ortega · 2017 · Endocrine Related Cancer
73. Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: Absence of toxicity due to saturating absorption
    Lee Jia, Karen M. Schweikart, Joseph E. Tomaszewski, John G. Page, Patricia E. Noker, Sarah A. Buhrow, Joel M. Reid, Matthew M. Ames, David H. Munn · 2007 · Food and Chemical Toxicology
74. The Selenazal Drug Ebselen Potently Inhibits Indoleamine 2,3-Dioxygenase by Targeting Enzyme Cysteine Residues
    Andrew C. Terentis, Mohammed Freewan, Tito S. Sempértegui Plaza, Mark J. Raftery, Roland Stocker, Shane Ross Thomas · 2009 · Biochemistry
75. IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1
    Erik A. Dill, Patrick Michael Dillon, Timothy N. J. Bullock, Anne M. Mills · 2018 · Modern Pathology
76. Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy
    Christina Kober, Julian Roewe, Norbert Schmees, Lars Roese, Ulrike Roehn, Benjamin Bader, Detlef Stoeckigt, Florian Prinz, Mátyás Gorjánácz, Helge Gottfried Roider et al. · 2023 · Journal for ImmunoTherapy of Cancer
77. The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation
    Carolina Manganeli Polonio, Kimberly A. McHale, David H. Sherr, David Rubenstein, Francisco Javier Quintana · 2025 · Nature Reviews Drug Discovery
78. Inflammation‐induced activation of the indoleamine 2,3‐dioxygenase pathway: Relevance to cancer‐related fatigue
    Sangmi Kim, Brian J. Miller, Michael Edward Stefanek, Andrew H. Miller · 2015 · Cancer
79. Cell‐autonomous control of interferon type I expression by indoleamine 2,3‐dioxygenase in regulatory CD19+ dendritic cells
    Anna Manlapat, David J. Kahler, Phillip Chandler, David H. Munn, Andrew L. Mellor · 2007 · European Journal of Immunology
80. Adoptive Transfer of Type 1 CTL Mediates Effective Anti–Central Nervous System Tumor Response: Critical Roles of IFN-Inducible Protein-10
    Fumihiko Nishimura, Jill E. Dusak, Junichi Eguchi, Xinmei Zhu, Andrea A. Gambotto, Walter J. Storkus, Hideho Okada · 2006 · Cancer Research
81. Design of a self-driven probiotic-CRISPR/Cas9 nanosystem for sono-immunometabolic cancer therapy
    Jifeng Yu, Bangguo Zhou, Shen Zhang, Haohao Yin, Liping Sun, Yinying Pu, Boyang Zhou, Yikang Sun, Xiao‐Long Li, Yan Fang et al. · 2022 · Nature Communications
82. The targeting of immunosuppressive mechanisms in hematological malignancies
    Mads Hald Andersen · 2014 · Leukemia
83. Chloroquine Modulates HIV-1-Induced Plasmacytoid Dendritic Cell Alpha Interferon: Implication for T-Cell Activation
    Jeffrey Martinson, Carlos Julio Montoya, Xiomara Úsuga, Rollie Ronquillo, ALAN L. LANDAY, Seema N. Desai · 2009 · Antimicrobial Agents and Chemotherapy
84. Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma
    Hao Liu, Zhenbin Shen, Zhenglin Wang, Xuefei Wang, Heng Zhang, Jing Qin, Xinyu Qin, Jiejie Xu, Yihong Sun · 2016 · Scientific Reports
85. PTEN‐deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells
    Thiago Vidotto, Fabiano Pinto Saggioro, Tamara Jamaspishvili, Deise Lucia Chesca, Clarissa Gondim Picanço de Albuquerque, Rodolfo Borges dos Reis, Charles H. Graham, David Monty Berman, David Robert Siemens, Jeremy Andrew Squire et al. · 2019 · The Prostate
86. In Vivo Uptake and Metabolism of α-[11C]Methyl- l -Tryptophan in Human Brain Tumors
    Csaba Juhász, Diane C. Chugani, Otto Muzik, Dafang Wu, Andrew Edward Sloan, Geoffrey R. Barger, Craig E. Watson, Aashit K. Shah, Sandeep Sood, Eser Lay Ergün et al. · 2005 · Journal of Cerebral Blood Flow & Metabolism
87. IDO1 is an Integral Mediator of Inflammatory Neovascularization
    Arpita Mondal, Courtney Smith, James B. DuHadaway, Erika Sutanto‐Ward, George C. Prendergast, Arturo Bravo‐Nuevo, Alexander J. Muller · 2016 · EBioMedicine
88. Host Indoleamine 2,3-Dioxygenase: Contribution to Systemic Acquired Tumor Tolerance
    Theodore S. Johnson, David H. Munn · 2012 · Immunological Investigations
89. Recent Considerations in the Application of RAPTA‐C for Cancer Treatment and Perspectives for Its Combination with Immunotherapies
    Magdalena Rausch, Paul J. Dyson, Patrycja M. Nowak-Sliwinska · 2019 · Advanced Therapeutics
90. Immune Checkpoint Inhibitor‐Based Strategies for Synergistic Cancer Therapy
    Mengying He, Tao Yang, Yuhan Wang, Mengyuan Wang, Xingye Chen, Dawei Ding, Yiran Zheng, Huabing Chen · 2021 · Advanced Healthcare Materials
91. Pharmacological Wnt Ligand Inhibition Overcomes Key Tumor-Mediated Resistance Pathways to Anti-PD-1 Immunotherapy
    Nicholas C. DeVito, Michael S. Sturdivant, Bala Thievanthiran, Christine Xiao, Michael P. Plebanek, April K.S. Salama, Georgia Marie Beasley, Alisha Holtzhausen, Veronica Novotny‐Diermayr, John H. Strickler et al. · 2020 · Cell Reports
92. Complete Reaction Mechanism of Indoleamine 2,3-Dioxygenase as Revealed by QM/MM Simulations
    Luciana Capece, Ariel Lewis-Ballester, Syun‐Ru Yeh, Dario Ariel Estrin, Marcelo Adrian Marti · 2011 · The Journal of Physical Chemistry B
93. Indoleamine 2,3-Dioxygenase Inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata
    Albán R. Pereira, Eduardo Vottero, Michel Roberge, A. Grant Mauk, Raymond J. Andersen · 2006 · Journal of Natural Products
94. Targeting T Cell Immunometabolism for Cancer Immunotherapy; Understanding the Impact of the Tumor Microenvironment
    Mary B. Mockler, Melissa Jane Conroy, Joanne Lysaght · 2014 · Frontiers in Oncology
95. Tryptophan Catabolism and Cancer Immunotherapy Targeting IDO Mediated Immune Suppression
    Adaobi E. Amobi, Feng Qian, Amit Anand Lugade, Kunle O. Odunsi · 2017 · Advances in experimental medicine and biology
96. Therapeutic Potential of Nitrogen Mustard Based Hybrid Molecules
    Yi‐Ming Chen, Yuping Jia, Weiguo Song, Lei Zhang · 2018 · Frontiers in Pharmacology
97. The role of regulatory T cells in alloantigen tolerance
    Varuna R. Aluvihare, Alexander G. Betz · 2006 · Immunological Reviews
98. Photodynamic Therapy Based on Nanoscale Metal–Organic Frameworks: From Material Design to Cancer Nanotherapeutics
    Qun Guan, Yan‐An Li, Wen‐Yan Li, Yu‐Bin Dong · 2018 · Chemistry - An Asian Journal
99. Inhibitory Substrate Binding Site of Human Indoleamine 2,3-Dioxygenase
    Changyuan Lu, Yu Hong Lin, Syun‐Ru Yeh · 2009 · Journal of the American Chemical Society
100. Current therapy of myelodysplastic syndromes
     Amer Methqal Zeidan, Yuliya P. L. Linhares, Steven D. Gore · 2013 · Blood Reviews